Other Science

Code Corporation’s Miniature Image Scan Engine Brings New Capabilities to Life Science

Retrieved on: 
Thursday, April 9, 2020
Technology, Packaging, Engineering, Audio, Video, Chemicals, Plastics, Health, Manufacturing, Other Science, Software, General Health, Hardware, Science, Other Manufacturing, Data management, Automation, Enhancement

Code Corporation today announced it has updated its OEM series of high-performance, miniature image scan engines.

Key Points: 
  • Code Corporation today announced it has updated its OEM series of high-performance, miniature image scan engines.
  • Codes CR8200 product line now boasts powerful image enhancement controls to improve the efficiency and accuracy of automated life science instruments.
  • View the full release here: https://www.businesswire.com/news/home/20200409005110/en/
    Code Corporation's CR8200 product line now boasts powerful image enhancement controls to improve the efficiency and accuracy of automated life science instruments.
  • In its most recent update, Code introduced fully customizable sub-image attention areas to create automated setpoints for image brightness and contrast.

TFF Pharmaceuticals Announces R&D Collaboration with the University of Georgia for a Universal Influenza Vaccine

Retrieved on: 
Thursday, April 9, 2020
University, Biotechnology, Education, Other Health, Health, Pharmaceutical, Other Science, Research, Infectious diseases, Science, Other Education, Viruses, RTT, Medical specialties, Articles, Influenza, Influenza vaccine, Vaccines, Pandemic, Vaccine, the University of Georgia’s Center for Vaccines and Immunology, the University of Texas at Austin, TFF Pharmaceuticals’ Thin Film Freezing technology platform, TFF Pharmaceuticals

Under the terms of the collaboration, TFF Pharmaceuticals, along with UT Austin and the University of Georgias CVI will collaborate to investigate TFF-formulated CVI recombinant universal influenza vaccines.

Key Points: 
  • Under the terms of the collaboration, TFF Pharmaceuticals, along with UT Austin and the University of Georgias CVI will collaborate to investigate TFF-formulated CVI recombinant universal influenza vaccines.
  • Influenza is a contagious viral infection that attacks the respiratory system infecting the nose, throat and sometimes the lungs.
  • Both seasonal and pandemic influenza continue to be major public health threats, said Glenn Mattes, CEO of TFF Pharmaceuticals.
  • This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Companys TFF platform and its dry powder versions of influenza vaccines.

ReAlta Life Sciences Strengthens Board of Directors with Election of Edward Heidt as Chair and Appointments of Dr. Jonathan Zalevsky and Christine Neikirk

Retrieved on: 
Thursday, April 9, 2020
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Marketing, Heidt, Need, Articles

In addition, we are delighted to tap into Jonathans extensive experience leading scientific innovation and R&D, and Chris deep management and marketing expertise.

Key Points: 
  • In addition, we are delighted to tap into Jonathans extensive experience leading scientific innovation and R&D, and Chris deep management and marketing expertise.
  • The collective strength of our board and leadership team positions us well to execute our goal of bringing forward new treatments that address life-threatening medical needs.
  • ReAlta has developed a novel platform with the potential to provide game-changing treatments for a number of unmet or under-addressed conditions, said Mr. Heidt.
  • Mr. Heidt has served on the ReAlta board since its founding, and holds more than 50 years of experience in international trade, manufacturing and distribution.

LabCorp and Ciox Health Enter Collaboration to Create Comprehensive Patient Data Registry

Retrieved on: 
Thursday, April 9, 2020
Research, Technology, Infectious diseases, Hospitals, Software, Pharmaceutical, Health, Data management, Science, Other Science, Burlington, North Carolina, LabCorp, Ciox Health, Health informatics, Health information management, LH, Industries, LabCorp, Ciox

LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Ciox Health, the leader in health information management for more than 30 years, today announced an agreement to collaborate on a comprehensive U.S.-based COVID-19 patient data registry.

Key Points: 
  • LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Ciox Health, the leader in health information management for more than 30 years, today announced an agreement to collaborate on a comprehensive U.S.-based COVID-19 patient data registry.
  • View the full release here: https://www.businesswire.com/news/home/20200409005379/en/
    LabCorp and Ciox Healths Real Word Data division will work closely to expedite this first-of-its-kind patient data registry.
  • Initially, LabCorp will analyze clinical de-identified data sets from its rapidly expanding diagnostic patient data sets.
  • Ciox Health, a leading health technology company, is improving patient health by transforming clinical data into actionable insights.

Scientist.com and HealthEconomics.Com Partner to Enable Online Sourcing of Health Economics and Outcomes Research (HEOR) and Real World Evidence (RWE)

Retrieved on: 
Thursday, April 9, 2020
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, RWE, Shortage, Economy

Partnering with HealthEconomics.Com to create a virtual marketplace for HEOR and RWE will allow critical research to continue despite widespread shelter-in-place orders.

Key Points: 
  • Partnering with HealthEconomics.Com to create a virtual marketplace for HEOR and RWE will allow critical research to continue despite widespread shelter-in-place orders.
  • The HEOR & RWE Marketplace addresses the long-standing problem of long contracting times, a lack of RFI standardization and a shortage of qualified suppliers.
  • The HEOR & RWE Marketplace is a powerful way to connect buyers and sellers, deliver faster science and speed up value-focused healthcare decisions.
  • HealthEconomics.Com is the worlds most comprehensive and credible CONNECTED COMMUNITY, serving as the global link to the health economics & outcomes research (HEOR), RWE (real-world evidence), and pharma market access stakeholder communities.

Coeus Consulting Group Continues its Expansion with the Hiring of Two Key Executives

Retrieved on: 
Thursday, April 9, 2020
Science, Other Science, Biotechnology, Pharmaceutical, Health, Consulting, Medical devices, Professional services, Business, Articles, Economy, Advisors, Consultant, Small business

Coeus Consulting Group, a leading boutique life science consulting firm, today announced it has hired two executives to help grow and manage the companys enhanced market access offerings.

Key Points: 
  • Coeus Consulting Group, a leading boutique life science consulting firm, today announced it has hired two executives to help grow and manage the companys enhanced market access offerings.
  • Gwiadzdinski brings more than 20 years of direct market access experience holding key strategic positions at large national payers including Prime Therapeutics and Cigna.
  • They are a key reinforcing step in the companys overall mission to bring executive-level consulting expertise to every client engagement.
  • Founded in 2009, Coeus Consulting Group is a boutique life science market access consulting firm supporting pharmaceutical, biotech, medical device, and payors in the U.S.

Production of Hand Sanitizer/Disinfectant at CHT USA to Help with Shortage

Retrieved on: 
Wednesday, April 8, 2020
Research, Infectious diseases, Construction & Property, Other Manufacturing, Textiles, Science, Chemicals, Plastics, Building Systems, Medical Supplies, Manufacturing, Other Science, Health, Viruses, Microbiology, Health, Disinfectants, Antiseptics, Hygiene, RTT, Coronaviridae, Hand sanitizer, CHT, Severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome-related coronavirus

CHT USA has started production of hand sanitizer/disinfectant to help with the shortage due to the novel coronavirus SARS-CoV-2 currently circulating.

Key Points: 
  • CHT USA has started production of hand sanitizer/disinfectant to help with the shortage due to the novel coronavirus SARS-CoV-2 currently circulating.
  • CHT USA started to plan for the production after the FDA released a temporary policy for production of hand sanitizers/disinfectant mid March 2020.
  • The CHT USA hand sanitizer/disinfectant is being produced at the Cassopolis, Michigan site as raw material availability allows.
  • View the full release here: https://www.businesswire.com/news/home/20200408005666/en/
    Chief of Police Cass County Sheriff Department, Brian Lavalle, picks up cases of CHT Disinfectant from Chad Pickle, CHT USA Supply Chain Manager and Thomas Gawlik, CHT USA CFO.

Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 8, 2020
Science, Other Science, Research, Communication design, Animal testing, Animal welfare, Bioethics, Advertising, Science experiments, Science, Knowledge, Alternatives to animal testing

The "Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035" report has been added to ResearchAndMarkets.com's offering.
  • This report from the publisher provides the strategists, marketers and senior management with the critical information they need to assess the global animal testing and non-animal alternative testing market.
  • Where is the largest and fastest growing market for the animal testing and non-animal alternative testing market?
  • The global animal testing and non-animal alternative testing market report to 2035 report from the publisher answers all these questions and many more.

AltaSea Launches ‘Project Blue @Home’ Virtual Education Program Featuring Titanic Discoverer Dr. Robert Ballard & LA Blue Economy CEOs

Retrieved on: 
Wednesday, April 8, 2020
Other Science, Research, Family, Training, Consumer, Environment, Teens, Children, Maritime, Alternative energy, Energy, Transport, Other Education, Other Natural Resources, Continuing, University, Primary, Secondary, Education, Science, Natural Resources

Project Blue @Home is an informal educational program that includes live video chats, video question-and-answer sessions and pre-packaged lessons.

Key Points: 
  • Project Blue @Home is an informal educational program that includes live video chats, video question-and-answer sessions and pre-packaged lessons.
  • Last month, AltaSea launched the first themed contest in its Project Blue @Weekends campaign, How the ocean can save the world.
  • Project Blues mission is two-fold: to position Los Angeles as the global center of the Blue Economy and provide students with a voice to help lead that effort.
  • McOsker will lead a live chat about the ocean economy as one segment of Project Blue @Home.

SCIEX and Intabio Collaborate to Accelerate Biopharma Drug Development

Retrieved on: 
Wednesday, April 8, 2020
Medical devices, General Health, Automotive, Hospitals, Science, Genetics, Clinical trials, FDA, Entertainment, Biotechnology, Other Manufacturing, Health, Other Science, Research, Manufacturing, Environment, Pharmaceutical, Articles, Natural sciences, Life sciences, Biopharmaceuticals, Capillary electrophoresis, Chromatography, Electrophoresis, Forensics, Polymerase chain reaction, Biomanufacturing, SCIEX, Intabio

This collaboration is geared to accelerate and transform biotherapeutic development and biomanufacturing.

Key Points: 
  • This collaboration is geared to accelerate and transform biotherapeutic development and biomanufacturing.
  • By coupling iCIEF separations directly to leading high resolution MS systems, the Blaze system eliminates a serious laboratory bottleneck for drug developers, said Lena Wu, Ph.D., Intabio CEO and co-founder.
  • Blaze integration with SCIEX flagship MS platforms will enable biopharma to accelerate critical decisions and ultimately reduce development timelines.
  • This work demonstrates our continued commitment to collaborate with key innovators to develop practical solutions for our biopharmaceutical customers, said Mani Krishnan, Vice President of Global Biopharma and Capillary Electrophoresis at SCIEX.